A B S T R A C T
Regardless of whether a randomized trial finds a statistically significant effect for an intervention or not, readers often wonder if the trial was large enough to be conclusive. To answer this question, we can estimate the required sample size for a trial by considering how commonly the outcome occurs, the smallest effect of clinical importance and the acceptable risk of falsely detecting or rejecting that effect. But when is a meta-analysis conclusive? We explain and illustrate the interpretation of Trial Sequential Analysis (TSA), a method increasingly used to answer this question. We conducted a conventional meta-analysis which suggested that, in adults undergoing cardiac surgery, remote ischemic preconditioning does not provide a statistically significant reduction in acute kidney injury (AKI) [12 trials, 4230 patients; relative risk 0.87 (95% confidence interval 0.74-1.02); P ¼ 0.08; I 2 ¼ 35%] or the risk of receiving acute dialysis [5 trials, 2111 patients; relative risk 1.15 (95% confidence interval 0.42-3.19); P ¼ 0.78; I 2 ¼ 59%]. TSA demonstrates that as little as a 20% relative risk reduction in AKI is unlikely. Reliably finding effects on acute dialysis and smaller effects on AKI would require much more evidence. Notably, conventional meta-analyses conducted at one of the two earlier time points may have prematurely declared a statistically significant reduction in AKI, even though at no point in the TSA was there sufficient evidence to support such an effect. With this and other examples, we demonstrate that the TSA can prevent premature conclusions from meta-analyses.
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I N T R O D U C T I O N
Meta-analyses commonly inform clinical practice, policy and future research [1] . There is an increasing recognition that they share vulnerabilities similar to randomized controlled trials (RCTs), such as finding statistically significant treatment effects that do not truly exist (type I error) and missing clinically important treatment effects that do (type II error). Thus, a meta-analysis should be subjected to at least the same requirements as an individual RCT to avoid these problems.
R E L A T I O N S H I P B E T W E E N M E T A -A N A L Y S E S A N D R C T s

Sample size
In a single RCT, there is a minimum sample size to reliably detect a clinically meaningful effect if it, in truth, exists [2] .
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When planning an RCT to evaluate an intervention's effect on the risk of an undesirable event, investigators calculate this sample size based on (i) the expected magnitude of the effect, (ii) the acceptable risk of type I error (typically a 5% chance that an effect will be falsely detected even if it does not exist), (iii) the desired statistical power (typically at least an 80% chance that an effect of the desired size will be detected if it exists) and (iv) the expected rate or the proportion of people in the control group who will experience the event (i.e. the control event proportion). Although the results of the trial are not known at the time of sample size calculation, the desired effect size should represent the smallest effect that patients and clinicians would deem important when considering the side effects, cost and inconvenience of using the intervention. The control event rate or proportion can be estimated from a pilot study or from previous studies conducted in the target population.
RCTs of insufficient size to detect clinically meaningful effects on patient-important outcomes are common. Although unreliable on their own, smaller trials can contribute information to a meta-analysis that, in principle, becomes more reliable than its parts. Even if several trials are combined, however, the total 'information size' (i.e. the meta-analysis sample size) may still be insufficient. We can begin to judge this by considering the same elements involved in the sample size calculation for a single RCT [3] .
Heterogeneity
In meta-analyses, we must also consider how the effect estimates differ between included RCTs. Some of the differences will be due to random chance because each RCT represents a (small) sample from an underlying population, but other differences may result because the RCTs test slightly different versions of the intervention or enroll fundamentally different patients. That is, the results may differ (be heterogeneous) on the basis of chance or for clinical reasons [4] . When substantial heterogeneity is thought to be due to factors other than the play of chance, meta-analyses using a 'random effects model' are typically preferred [5] . The measure by which we quantify heterogeneity and the type of statistical model we use to combine study results will ultimately influence the meta-analysis results and required information size.
Preventing chance findings from early and multiple comparisons Figure 1 illustrates the next point. In an RCT, a Data Monitoring Committee looks at the data at prespecified intervals to determine if differences in outcomes between the intervention and control groups are so convincing that the trial should be stopped early or the probability of detecting a benefit is so small that continuing the trial is futile. One can think of there being a boundary for declaring a statistically significant effect-if the difference between the groups is large enough to cross that boundary, we would say that the difference is statistically significant. Early on-when relatively few patients have been recruited-there are often substantial imbalances between two groups such that patients in one group may be sicker and more likely to experience the event (regardless of the intervention). There could be a statistically significant difference in outcomes between two groups from an imbalance in important baseline characteristics between two groups rather than any effect of the intervention. This spurious difference can be in either direction. Only as more patients are recruited does the estimated effect begin to reflect the true effect of the intervention. To address this, we can construct a better monitoring boundary adjusted for the number of patients in the study, such that early in recruitment, the effect would have to be larger to be deemed statistically significant than if we compare the groups FIGURE 1: (A) In a single trial, effect estimates from early data fluctuate by chance and can reach nominal statistical significance (the conventional boundary) at several time points even if no effect exists. Analyses at these time points would arrive at erroneous conclusions. Monitoring boundaries (dotted lines) adjusted for sample size and the number of comparisons can prevent spurious findings from early and multiple testing. The effect estimate becomes stable beyond a certain sample size and more data does not change the results. If a monitoring boundary is crossed before this time, we can confidently declare efficacy or futility. (B) The same concepts apply to metaanalyses. Patients are 'recruited' into meta-analyses in discrete intervals (i.e. with the addition of each new trial), adding new information. Only after enough information is available (or a monitoring boundary is crossed) can we make confident conclusions. Larger boxes represent larger trials.
later on when more patients have been recruited and there is less risk of chance imbalances. Furthermore, every time we compare the groups while participants are still accruing, we increase the risk that any observed statistically significant difference is actually due to chance (type I error). Upon completion of the RCT, the true risk of type I error (i.e. the P-value) could be much larger than that presented in the research paper, giving false certainty in the findings. One method to prevent this is sequential analysis that adjusts the test statistics or the P-value threshold downward to account for previous hypothesis tests. Meta-analyses of the same question are conducted periodically as new evidence becomes available, with hypothesis tests to, typically, look for the nominal P ¼ 0.05 significance level. If reached, researchers may conclude that an intervention is effective; alternatively, they may conclude that 'further research is required' if P > 0.05. Hypothesis tests may even be conducted as every new trial is added to the evidence base-a process known as cumulative meta-analysis-to identify when the answer is clear, potentially avoiding years of unnecessary research [6] . Such periodic updating of a meta-analysis is similar to interim monitoring in a single trial [3, 7] . If we conduct a meta-analysis after just a few small RCTs have been published, there is high risk that the differences between the combined treated and untreated groups arose because of chance imbalances. This risk is lower when meta-analysis is conducted after more RCTs have been published. Thus, valid assertions of statistical significance in meta-analyses require accounting for the number of included patients and for the previous hypothesis testing. One method is to use monitoring boundaries that are adjusted as RCTs are added to a meta-analysis, analogous to interim analyses in a single RCT [3, 8] .
Trial Sequential Analysis
Researchers at the Copenhagen Trials Unit extended these ideas to establish Trial Sequential Analysis (TSA) [9] . This is a cumulative random effects meta-analysis method that estimates a 'required information size' (i.e. required meta-analysis sample size) using the same framework as sample size calculation for an individual RCT, but additionally accounting for heterogeneity and multiple comparisons when new RCTs are added. Furthermore, before the required information size is reached, TSA constructs monitoring boundaries to determine when an estimated effect is so convincingly large (or small) that the conclusions are unlikely to change with more evidence. The approach is now increasingly encountered in published systematic reviews.
Example: remote ischemic preconditioning for renoprotection in cardiac surgery
Remote ischemic preconditioning (RIPC) is a simple intervention hypothesized-by potentially protecting against ischemia reperfusion injury [10] -to improve cardiovascular and renal outcomes in patients undergoing procedures that may deliver an ischemic insult. Patients receive several controlled cycles of intermittent ischemia and reperfusion before their procedure, typically through inflating and deflating a pneumatic tourniquet. A 2014 meta-analysis suggested-based on marginal statistical significance-that RIPC may offer a 30% relative reduction in risk of acute kidney injury (AKI) for patients undergoing cardiac and vascular interventions [11] . A 2015 RCT of 240 patients undergoing cardiac surgery showed a substantially lower incidence of AKI in the RIPC group [12] . Shortly thereafter, three larger RCTs demonstrated no effect [13] [14] [15] . This now prompts the question of whether more trials are needed to better understand the effects of RIPC or if research funds and efforts should be directed to more promising interventions. We undertook a systematic review of RCTs and a meta-analysis with TSA to assess the effect of RIPC on AKI in adult patients having cardiac surgery.
Selection of trials and outcomes
We searched Medline and Embase to 9 February 2016 for RCTs of RIPC (full details in Supplementary data, Appendix). RCTs reporting dichotomous or categorical renal outcomes were eligible (i.e. either creatinine-based AKI or initiation of renal replacement therapy). We considered acute initiation of dialysis as part of the primary AKI outcome but also analyzed it separately. Creatinine-based outcomes had to be collected prospectively to limit the risk of surveillance bias. We did not consider AKI outcomes determined on the basis of noncreatinine biomarkers. Trials or study arms evaluating ischemic postconditioning were not eligible.
Two reviewers screened the titles and abstracts of 302 articles with excellent agreement (j ¼ 0.84; a third reviewer resolved disagreements) and the full texts of 75 with perfect agreement (Supplementary data, Figure S1 ). Supplementary data, Table S1 summarizes the study characteristics. Twelve RCTs (Supplementary data, References S1-S1) studied AKI [1130 events; 4230 patients; median 135 patients (range 31-1521), median control event proportion 28.5%]. Five RCTs (Supplementary data, References S1, S5, S8, S10 and S12) contributed dialysis data [63 events; 2111 patients; median 240 patients (range 86-1385); median control event proportion 1.3%].
Risk of bias and fragility of treatment effect from individual trials. Eleven RCTs were at low risk of bias based on the method of randomization, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, description of withdrawals and dropouts and the amount and handling of missing outcome data [16] ; one that contributed AKI but not dialysis data was at moderate risk. We calculated the Fragility Index as defined by Walsh et al. [17] for individual RCT results that demonstrated statistical significance (P < 0.05). The Fragility Index quantifies the minimum number of event-free patients in the group with the lower event incidence who, when reclassified as having experienced the event of interest, are sufficient to make a statistically significant between-group difference not significant. Three RCTs found statistically significant reductions in AKI by RIPC (Supplementary data, References S2, S7 and S8), but their low Fragility Index indicates that the misclassification of only five, one and two events, respectively, would have rendered their results nonsignificant. One RCT found a reduced risk of acute dialysis by RIPC (Fragility Index 2) (Supplementary data, Reference S8). . Cumulative meta-analysis shows how the summary effect estimate evolved as RCTs were published. If a metaanalysis was conducted immediately after the publication of the second and eighth RCTs (when 270 and 977 patients had been included, respectively), it would have found a statistically significant reduction in AKI.
TSA methods. We conducted TSA using Trial Sequential Analysis software 0.9 (Copenhagen Trials Unit, Denmark) [18] . We assumed 5% as an acceptable risk of type I error (a) and used a DerSimonian-Laird random effects model. The following assumptions commonly vary between reviews and have a substantial impact on results (Table 1) :
• Minimum desired effect size: we selected a 25% relative risk reduction (RRR) in AKI a priori. This is a reasonable expectation of acute treatments if they are to translate into patient-important benefits. In sensitivity analyses, we calculated the information sizes required to detect RRRs of 20, 15 and 10% in AKI.
• Statistical power: 80%. One could argue that the standards for meta-analyses should be higher than for any individual trial due to their potential impact on policy and practice, so we repeated the analysis with 90% power.
• Control event proportion: 28.5% (median across control groups). This is an estimate that may not reflect future studies. In our example, more recent RIPC trials have enrolled higher-risk patients than early trials. In sensitivity analyses, we assumed proportions of 20 and 40%.
• Measure of heterogeneity: diversity (D 2 ) [19] . This is similar in concept to the inconsistency index (I 2 ) commonly used in conventional meta-analyses: both represent statistical heterogeneity, but diversity may be more reliable for estimating required information size when the evidence base includes mostly small trials [4] . We used I 2 in a sensitivity analysis.
• Amount of heterogeneity: 64% (the observed diversity).
Because it can greatly affect the required information size estimate, it is useful to perform sensitivity analyses with plausible alternatives; we used 30%.
We also calculated the information size required to detect a 10% RRR in acute dialysis (a ¼ 5%, 80% power, 1.3% control event proportion, observed diversity). In sensitivity analyses, we used a less conservative 5% control event proportion and 30% diversity ( Figure 3 ).
Results and interpretation of TSAs. Figure 2 summarizes TSA results for AKI. When the required information size has been reached or the cumulative Z curve crosses a monitoring boundary, a sufficient amount of evidence for or against the anticipated intervention effect has been reached such that further trials are unlikely to change the conclusion. In contrast, the evidence is insufficient to reach a firm conclusion if the curve does not cross a monitoring boundary and the required information size has not been reached. Our analysis shows that the accrued information size (4230 patients) has exceeded the required information size (3256 patients) to confirm or exclude a 25% RRR with FIGURE 2: Forest plots from (A) conventional and (B) cumulative random effects meta-analyses. Relative risk <1 favors the conclusion that RIPC reduces risk compared with usual care; relative risk >1 favors the conclusion that RIPC increases risk compared with usual care. The Fragility Index is calculated for statistically significant results only; more robust results have higher scores. Analyses performed using Stata 13.1 (StataCorp, College Station, TX, USA). Although underpowered, Egger's test found no significant evidence of small study bias for AKI (P ¼ 0.16) and suggested the possibility of bias for acute dialysis (P ¼ 0.05). . Thus, it is highly unlikely that RIPC would reduce the risk of AKI by 25% or that further trials would change this conclusion. The evidence was sufficient to exclude a 20% RRR with moderate confidence since the futility boundary was crossed, indicating that the addition of future trials is unlikely to detect an effect of this magnitude. Because power was set to 80%, there is a 20% chance that this futility statement is false. To make similarly confident conclusions, RRRs of 15 and 10% under the same assumptions, we would require a total of 9385 and 21 427 patients, respectively. Importantly, meta-analyses based on traditional hypothesis testing conducted at either of two points in time when the conventional monitoring boundary was crossed would have falsely identified RIPC as significantly reducing AKI. TSA prevented this premature conclusion.
We would require 814 249 patients to reliably confirm or exclude a 10% RRR in acute dialysis assuming the observed 1.3% median control group incidence and diversity of 72%. A total of 81 170 patients would be required under more optimistic assumptions of 30% diversity and 5% control event proportion. The available information was insufficient to construct monitoring boundaries for acute dialysis.
Additional examples. We additionally performed TSA on nine published meta-analyses (summarized in Table 2 ) from two systematic reviews: one comparing convective to diffusive dialysis for chronic kidney failure [20] and the other comparing preemptive correction of arteriovenous access stenosis to deferred salvage [21] . In eight of the nine meta-analyses, TSA suggested that there is insufficient evidence to confirm or exclude a 20% RRR in negative outcomes despite four of these suggesting statistically significant benefits using conventional methods. The last TSA suggested, with moderate confidence, The accrued information size (i.e. the meta-analysis sample size) depends on study selection criteria and is constant for a given outcome. In our example, 4230 patients were included in the AKI meta-analysis. Some parameter choices are very common, so we have kept them constant throughout all of our analyses: hypothesis tests were two-sided, acceptable type 1 error rate (a) was 5%, a DerSimonian-Laird random effects model was used to combine results [readers may encounter other methods (e.g. Biggerstaff-Tweedie, Sidik-Jonkman)], sequential efficacy and harm monitoring boundaries that control for type I error were constructed using the Lan-DeMets version of the O'Brien-Fleming a-spending function and futility monitoring boundaries that control for type II error were constructed with an O'Brien-Fleming b-spending function. We assumed that a meta-analysis may have been performed after the publication of each trial, although these monitoring boundaries are relatively insensitive to this assumption. 
L I M I T A T I O N S O F T S A
When presented with a meta-analysis of two small trials, most readers easily agree that further research is needed, but this becomes less clear as more trials are added. TSA is an increasingly accepted approach to this problem. Like all meta-analyses, it is limited by publication bias, bias from individual RCTs of poor methodological quality and important differences between pooled studies. Awareness and transparency of its assumptions are critical because the determination of required information size is not an exact science. People may disagree about the acceptable risk of erroneously detecting an effect that does not exist (type I error) or failing to detect one that does (type II error), and there is nothing inherently correct about the traditionally chosen numbers. People may also disagree about what constitutes a meaningful effect. This is well illustrated by discrepant conclusions from a recent meta-analysis and TSA on the same topic [22] . Despite minor differences in included FIGURE 3: AKI TSA plot with Lan-DeMets boundaries and estimates of the diversity-adjusted required information size (i.e. meta-analysis sample size) to detect a 25% relative risk reduction (RRR) with a ¼ 0.05 and (A) 80% power and (B) 90% power; (C) 20% RRR with 80% power. Z-score þ1.96 represents the 'conventional' efficacy boundary (P ¼ 0.05); it was spuriously crossed after the second and eighth trials, but the monitoring efficacy boundary was never crossed. In (A), the accrued information size exceeds the required information size. In (B), the accrued information size has (nearly) reached the required information size and the futility boundary was crossed. Both suggest that further evidence is highly unlikely to find RRR 25%. In (C), the required information size has not been reached but the futility boundary has, suggesting that RIPC is unlikely to offer RRR 20%. All analyses were two-sided, with the negative (harm) side omitted for simplicity of demonstration because the Z-curve never went below zero.
RCTs, the analysis estimated an effect similar to ours [RR 0.83 (95% CI 0.70-0.99)], but concluded that more RCTs are highly warranted because, in that analysis, the monitoring boundary for efficacy had not been crossed and the required information size (10 079 patients) was not reached. This estimate was based on a 17% RRR (observed from the meta-analysis) with 80% power and a control event proportion of 23.7%. The minimally important effect should reflect clinical relevance; a large RCT suggests that a 17% RRR in mild perioperative AKI will not improve patient-important outcomes [23] .
TSA methods continue to evolve. They commonly assume that a meta-analysis is performed each time a new RCT is published and that the results inform the decision to undertake a subsequent RCT. This is clearly not the case. Several RCTs currently under way may contribute AKI data; they were planned before the results of recent RCTs and this systematic review were known. Furthermore, TSA can tell us that additional RCTs are necessary and roughly estimate the number of patients or events that these RCTs need to contribute in total, but it remains unclear how this information should be used when In the original publication the 95% CI was 0.70-1.07 because it was estimated using the Knapp-Hartung method not available in the TSA software. We used the common DerSimonian-Laird random effects method. In the original publication the 95% CI was 0.58-0.97 because it was estimated using the Knapp-Hartung method not available in the TSA software. We used the common DerSimonian-Laird random effects method. [24] . Due to between-trial variance, a single RCT may never be sufficient to make some meta-analyses conclusive and it is unclear how many smaller RCTs are necessary and how many patients each should enroll [25] . Despite its limitations, TSA is more informative than subjective assessments of the adequacy of a body of evidence. Although additional approaches to limit false inferences from meta-analyses have been described [26] [27] [28] [29] , they have other limitations and have not received similar attention.
Whatever the method, the concept remains the same: metaanalyses are influential and should be held to at least the same standards as RCTs. We hope this article makes one approach more transparent to readers.
S U P P L E M E N T A R Y D A T A
Supplementary data are available online at http:// ndt.oxfordjournals.org.
A U T H O R S ' C O N T R I B U T I O N S
P.S.R. takes responsibility for the integrity of the work. He is the guarantor. P.S.R.: study concept and design, drafting of the manuscript and study supervision; P.S. 
C O N F L I C T O F I N T E R E S T S T A T E M E N T
The authors report no conflicts of interest. This work did not require ethics approval. The results presented in this article have not been published previously in whole or part.
